1. Sign our petition calling on Cochrane to withdraw their review of Exercise Therapy for CFS here.
    Dismiss Notice
  2. Guest, the 'News in Brief' for the week beginning 15th April 2024 is here.
    Dismiss Notice
  3. Welcome! To read the Core Purpose and Values of our forum, click here.
    Dismiss Notice

Role of mitochondria, oxidative stress and the response to antioxidants in ME/CFS: a possible approach to SARS-CoV-2 ‘long-haulers’?, 2020, Tate et al

Discussion in 'Long Covid research' started by Trish, Nov 28, 2020.

  1. Trish

    Trish Moderator Staff Member

    Messages:
    52,372
    Location:
    UK
    Review article:

    Role of mitochondria, oxidative stress and the response to antioxidants in myalgic encephalomyelitis/chronic fatigue syndrome: a possible approach to SARS-CoV-2 ‘long-haulers’?


    EmilyWood, Katherine H.Hall, WarrenTate (University of Otago, New Zealand)


    https://www.sciencedirect.com/science/article/pii/S2095882X20300839

     
    Hutan, Michelle, geminiqry and 15 others like this.
  2. Hutan

    Hutan Moderator Staff Member

    Messages:
    26,941
    Location:
    Aotearoa New Zealand
    The discussion about some of the papers I have looked at is not reassuring.

    For example work in 2015 by the Castro-Marrero team on CoQ10 is discussed here; CoQ10 - Coenzyme Q10

    (A more recent study by the same team further illustrates the problems with their studies - Effect of Dietary Coenzyme Q10 Plus NADH Supplementation on Fatigue Perception and Health-Related QoL in ... ME/CFS, 2021, Castro-Marrero et al.)

    MitoQ is a supplement developed by Otago University researchers - they are friends of Warren Tate, and he and his team have been trying to show that MitoQ can be helpful in ME/CFS. This study does report on the Mendus study which had a blinded investigation and an unblinded one. The blinded investigation found that MitoQ did not help ME/CFS symptoms at all, while in the unblinded investigation it appeared to. The authors here suggest that issues with the lack of confirmation of diagnosis and inability to confirm compliance with the dosage might have caused problems. That's potentially true, but there was not even a glimmer of a suggestion of a result in the blinded investigation.

    I think this paper is useful as a list of relevant papers, but the analysis of them needed to be stronger.

    This conclusion just is not warranted on the studies done to date.
    I really want the Otago team to be producing great work - Warren Tate is a lovely man who has been a strong supporter of people with ME/CFS, has run the ME/CFS research programme on a shoestring for a long time and who keeps bringing young researchers into the field. And these are New Zealand researchers. But this paper does not show the necessary level of skepticism about the evidence base for CoQ10 and MitoQ as treatments for ME/CFS.

    I know of a lot of people with ME/CFS who are spending money they can't afford in order to take MitoQ in the hope that it is doing something. The ongoing promotion of MitoQ by the Otago team is causing harm if the supplement doesn't really help. Rather than letting the possibility of a treatment drag on, it would be relatively easy to organise a blinded trial of MitoQ here in New Zealand. People could have their GPs confirm that they have an ME/CFS diagnosis, the MitoQ company could supply the tablets. There are people who could help organise a trial.

    (Sorry, have made an edit to recognise that this paper could not have included results from the Castro-Marrero 2021 paper.)
     
    Last edited: Aug 10, 2021
    Trish, Wyva and SNT Gatchaman like this.

Share This Page